STOCK TITAN
  1. Home
  2. News
  3. PBLA

Panbela Therapeutics, Inc. - $PBLA STOCK NEWS

Welcome to our dedicated page for Panbela Therapeutics news (Ticker: $PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Panbela Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Panbela Therapeutics's position in the market.

News
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) provided a business update and reported financial results for Q3 2023. Recent highlights include collaborations, clinical trial updates, and financial/business developments, such as the divestiture of assets within the pediatric neuroblastoma program to US WorldMeds for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. The company also announced new patents in China, Chile, and Australia, and a Phase 2 trial in castration resistant metastatic prostate cancer (mCRPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
-
News
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
Panbela Therapeutics, Inc. has entered into agreements with certain holders of its existing warrants to exercise their warrants at a reduced price of $0.78 per share. The exercise of the warrants is expected to generate approximately $1.9 million in gross proceeds. The new warrants will be exercisable into up to 4,260,000 shares of common stock at an exercise price of $0.78 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.21%
Tags
none
-
News
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
Rhea-AI Summary
Panbela Therapeutics announces the publication of preclinical and clinical data on DFMO treatment in recent onset type 1 diabetes. The data shows that DFMO treatment may preserve β cell function and improve patient outcomes. The Phase 1 clinical study demonstrated that CPP-1X was well tolerated and showed a dose-dependent inhibition of ODC. The study also found that treatment with CPP-1X stabilized C-peptide levels compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.2%
Tags
clinical trial
News
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Rhea-AI Summary
Panbela Therapeutics, Inc. has announced the validation of its European patent for a novel process to produce SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., claims a reduced number of synthetic steps from seventeen to six, providing a scalable, efficient, and cost-effective manufacturing process. The patent is valid until 2039.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
-
News
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
Rhea-AI Summary
Panbela Therapeutics announces acceptance of abstract on SBP-101 and CPP-1X research in multiple myeloma for online publication
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
News
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences earnings
News
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Rhea-AI Summary
Panbela Therapeutics announces Issue Notification for Chinese patent 201980010826.7 in collaboration with Syngene International Ltd. The patent claims a novel process to produce SBP-101 with reduced synthetic steps. Advantages include scalability, efficiency, and cost-effectiveness. This expands coverage into China and Asia, potentially reducing production costs and improving competitiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
-
News
Panbela to Present at the LD Micro Investor Conference
Rhea-AI Summary
Panbela Therapeutics, Inc. to present at LD Micro Conference on October 4, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
conferences
-
News
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
Rhea-AI Summary
Panbela Therapeutics announces the issuance of a Chilean patent for its lead investigational product, Flynpovi, developed in collaboration with Sanofi. The patent covers a fixed dose formulation of eflornithine and sulindac for the treatment of patients with Familial Adenomatous Polyposis (FAP). The patent is valid until 2036 and has been issued in multiple countries. This expands Panbela's patent portfolio and supports their global clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
News
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Panbela Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
Stock PBLA logo
Panbela Therapeutics, Inc.

Nasdaq:PBLA

PBLA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PBLA Stock Data

2.86M
4.85M
0%
0.16%
3.07%
Biotechnology
Healthcare
Link
United States of America
Waconia